secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2025-07-08T23:59:59+00:00
Accession:  0001615219-25-000066
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Salarius stockholders approve reverse stock split and Nasdaq 20% share issuance
-------------------------------------------------------------------------------

- Reverse stock split approved at ratio of 1:4 to 1:40; Board retains discretion on timing and exact ratio.
- Nasdaq 20% issuance proposal passed, authorizing shares under December 2024 purchase agreement with C/M Capital Master Fund, LP.
- Adjournment proposal passed but was not needed; quorum of 37.10% (789,213 of 2,127,286 shares) was present.
- Reverse split vote: 561,364 for, 224,901 against; issuance vote: 124,631 for, 73,764 against (589,723 broker non-votes).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000066/0001615219-25-000066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000066/flks-20250708.htm
  HTML page:      https://secwatch.observer/filing/0001615219-25-000066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer